)
Visual
test
Replimune Group
Replimune Group (REPL) investor relations material
Replimune Group Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 earnings summary3 Feb, 2026
Executive summary
Clinical-stage biotech focused on oncolytic immunotherapies, with lead candidate RP1 in advanced melanoma and other skin cancers, and additional candidates RP2 and RP3 in development.
RP1 BLA for advanced melanoma received a Complete Response Letter (CRL) from the FDA in July 2025; BLA was resubmitted and accepted with a new PDUFA date of April 10, 2026; commercial readiness underway.
Ongoing clinical trials include confirmatory phase 3 (IGNYTE-3) for RP1, phase 1b/2 ARTACUS for transplant recipients, and REVEAL phase 2/3 for RP2 in metastatic uveal melanoma and liver-focused studies.
Loan agreement amended with Hercules Capital, drawing $35M and potential for $120M more post-approval; debt repayment delayed to 2027, extending cash runway into Q1 2027.
Financial highlights
Net loss for the quarter ended December 31, 2025 was $70.9 million, compared to $66.3 million in the prior year quarter; net loss per share was $0.77 versus $0.79 year-over-year.
Net loss for the nine months ended December 31, 2025 was $240.7 million, up from $173.2 million year-over-year.
Cash, cash equivalents, and short-term investments totaled $269.1 million as of December 31, 2025, down from $483.8 million at March 31, 2025.
Research and development expenses for the quarter were $53.1 million, up from $48.0 million year-over-year; for the nine months, $168.9 million, up from $135.5 million.
Selling, general and administrative expenses for the quarter were $18.7 million, up from $18.0 million; for the nine months, $77.7 million, up from $46.8 million.
Outlook and guidance
Cash runway expected to fund operations late into Q1 2027, including potential commercialization of RP1, assuming successful regulatory approval.
If RP1 is not approved, company may need to restructure and reprioritize its pipeline.
Ongoing engagement with FDA regarding RP1 BLA; interim analysis for IGNYTE-3 phase 3 trial planned for H2 2027.
REVEAL Phase 2/3 trial for RP2 in metastatic uveal melanoma actively enrolling; Phase 2/3 transition expected Q1 2027.
RP1 launch funding post-approval
RP2 accelerated approval path
Cash runway sustainability beyond Q1 2027
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Latest summaries
- TimeTickerHeadlineOpen
- XEL
Ongoing EPS reached $3.80 in 2025; 2026 guidance is $4.04–$4.16 with a $60B capital plan. - EL
Strong Q2 results and raised FY26 outlook, with sales and margins up despite headwinds. - KCR
Record profitability and strong orders in 2025; stable outlook for 2026 amid uncertainties. - 532539
Record Q3 FY26 revenue and profit growth, major expansions, and strong industry outlook. - HAE
Gross margin and net income rose despite lower revenue; guidance for EPS and cash flow increased. - QIGD
Revenue up 18% but net profit down 15% as higher costs and dividends reduced margins and equity. - MYCR
Record annual sales, Q4 order drop, strong Global Technologies, and four acquisitions. - 532548
Revenue up 18.4% YoY, margin gains, and capacity expansions support a positive outlook. - THERMAX
Profit after tax rose 80% and order booking grew 34%, led by Infra and data center wins. - LPG
Net income more than doubled on strong TCE rates, higher revenues, and efficient fleet operations.
Next Replimune Group earnings date
Q4 202621 May, 2026
Replimune Group
Next Replimune Group earnings date
Q4 202621 May, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Replimune Group Inc. is a biotechnology company focused on the development of oncolytic immunotherapies for the treatment of cancer. The company leverages its proprietary Immulytic platform to engineer viruses that selectively replicate within tumors, stimulating an immune response to attack the cancer cells. Replimune's therapies are designed to be used in combination with other immuno-oncology treatments to enhance their effectiveness. The company targets various forms of cancer, aiming to improve outcomes for patients with difficult-to-treat malignancies. The company is headquartered in Woburn, Massachusetts, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage